Drugs / GSK1144814
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01181908 | Nov → Dec 2009 | alcohol dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01090440 | Sep → Oct 2009 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01209039 | Jul → Oct 2009 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01381419 | Oct 2008 → Apr 2009 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1144814 | “The primary objective of this study is to investigate the CNS effects of co-administration of GSK1144814 with alcohol.” NCT01181908 ↗ |
| Action | Inhibit | “potent, insurmountable antagonist at human neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors” NCT01090440 ↗ |
| Route | Oral | “single oral doses of GSK1144814” NCT01090440 ↗ |